Search | Page 10 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: Retrospective analysis of survival after long-term follow-up

    ... Hypomethylating agents (HMA), such as 5- azacitidine or decitabine , are currently used to treat patients ...

    Research Article last updated 05/26/2015 - 12:53pm.

  2. Current and novel therapeutic approaches in myelodysplastic syndromes

    ... for its treatment: lenalidomide , 5- azacitidine , and decitabine . These therapies can be effective in ... and reduction in bone marrow blasts . 5-azacitidine has also been shown to improve overall survival. However, there ...

    Research Article last updated 05/26/2015 - 12:13pm.

  3. 5-Azacitidine efficacy and safety in patients aged >65 years with myelodysplastic syndromes outside clinical trials

    ... The efficacy and safety of azacitidine in elderly patients (aged >65 years) with myelodysplastic ... trials are reported. Thirty-eight patients with MDS received azacitidine (75 mg/m(2), schedule 5+2 +2): seven patients were classified as ...

    Research Article last updated 06/15/2012 - 2:13pm.

  4. Thrombopoiesis-stimulating agents and myelodysplastic syndromes

    ... efficacy of disease-modifying therapies, such as azacitidine or lenalidomide . The recombinant human ...

    Research Article last updated 03/04/2015 - 10:20am.

  5. More is better: Combination therapies for myelodysplastic syndromes

    ... FDA-approved medications for MDS; lenalidomide , azacitidine , and decitabine . The role of these agents is to ...

    Research Article last updated 03/03/2015 - 2:41pm.

  6. Current therapy of myelodysplastic syndromes.

    ... (MDS). On the therapeutic front, the approval of azacitidine , decitabine , and lenalidomide in the last ...

    Research Article last updated 09/03/2013 - 12:03pm.

  7. Myelodysplastic syndromes: therapy and outlook

    ... (HSCT), approved therapies such as lenalidomide , azacitidine , and decitabine are available for those who previously ... achieve hematologic improvement and enhance quality of life. Azacitidine is the only treatment to show a significant survival advantage in ...

    Research Article last updated 07/31/2012 - 1:27pm.

  8. Myelodysplastic syndromes: health care management considerations.

    ... two hypomethylating agents approved for this indication-- azacitidine and decitabine --in terms of proven effectiveness, safe ... only with continued discussion and study. The therapies azacitidine and decitabine may offer a good model for decision making to drive ...

    Research Article last updated 10/11/2011 - 5:58pm.

  9. Recent developments in myelodysplastic syndromes

    ... in the United States (US). US regulatory approval of azacitidine , decitabine , and lenalidomide between 2004 and ...

    Research Article last updated 10/02/2014 - 10:30am.

  10. Update on the pharmacotherapy for myelodysplastic syndromes

    ... of these complex malignancies: lenalidomide , azacitidine and decitabine . AREAS COVERED: This review ...

    Research Article last updated 08/21/2014 - 9:23am.